The Effect of Disclosure of PrEP Use on Adherence Among African Young Women in an Open-Label PrEP Study: Findings from HPTN 082
-
Published:2023-09-28
Issue:
Volume:
Page:
-
ISSN:1090-7165
-
Container-title:AIDS and Behavior
-
language:en
-
Short-container-title:AIDS Behav
Author:
Beauchamp GeethaORCID, Hosek Sybil, Donnell Deborah, Chan Kwun C. G., Anderson Peter L., Dye Bonnie J., Mgodi Nyaradzo, Bekker Linda-Gail, Delany-Moretlwe Sinead, Celum Connie,
Abstract
AbstractTo develop effective PrEP adherence interventions, it is important to understand the interplay between disclosure of pre-exposure prophalxis (PrEP) use, social support, and PrEP adherence. We leveraged the HPTN 082 study conducted among 451 adolescent girls and young women (AGYW) (ages 16 to 25 years, 2016 to 2019) in South Africa and Zimbabwe. Among the 349 who had month three disclosure and PrEP adherence data, 60% (n = 206) felt supported by adults, and 89% (n = 309) disclosed PrEP use to at least one person. PrEP disclosure was not associated with increased adherence, measured by intracellular tenofovir-diphosphate concentrations in dried blood spots. Women who reported having supportive adults, and disclosed to their parents, had higher adherence at 6 months with an increase of 177 fmol/punch (95% CI 12 to 343, t = 2.11, p = 0.04). PrEP interventions that help AGYW identify supportive relationships and effectively communicate the benefits of PrEP may improve PrEP adherence.Clinicaltrials.gov ID number: NCT02732730.
Funder
Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Public Health, Environmental and Occupational Health,Social Psychology
Reference47 articles.
1. UNAIDS. Joint United Nations Programme on HIV/AIDS. UNAIDS data 2020. Geneva, Switzerland. UNAIDS. 2020;436. https://www.unaids.org/sites/default/files/media_asset/2020_aids-data-book_en.pdf 2. Myers L, Scientist B, Town C. Rethinking PrEP for adolescent girls and young women. IAPAC. 2019;(June). 3. Gill K, Pidwell T, Dietrich J, Gray G, Bennie T, Kayamba F, et al. A Demonstration open label study to assess the acceptability, safety and use of Truvada pre-exposure prophylaxis in healthy, HIV uninfected adolescents, 15–19 years of age. In: International AIDS society conference (IAS) on HIV science. Paris, France; 2017. https://mtnstopshiv.org/sites/default/files/attachments/KATHERINE-IAS2017MTNplenaryfinalKatherine.pdf 4. Celum C, Hosek S, Tsholwana M, Kassim S, Mukaka S, Dye IDBJ, et al. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: results from HPTN 082, a randomized controlled trial. PLoS Med. 2021;18(6):e1003670. https://doi.org/10.1371/journal.pmed.1003670. 5. Celum CL, Gill K, Morton JF, Stein G, Myers L, Thomas KK, et al. Incentives conditioned on tenofovir levels to support PrEP adherence among young South African women: a randomized trial. J Int AIDS Soc. 2020;23(11):e25636.
|
|